Skip to main content
. 2018 Jan 26;154(2):285–297. doi: 10.1111/imm.12884

Figure 7.

Figure 7

Recombinant modified vaccinia virus Ankara (rMVA) ‐CD70 confers protection against a lethal virus infection in the absence of CD4 T cells. MHC II −/− mice were immunized intravenously with 5 × 107 TCID 50 rMVA, rMVA‐CD70 or rMVA + 200 μg anti‐CD70 (FR70) on days 0 and 28. On day 56 after immunization, mice were infected intranasally with 1 × 105 TCID 50 ectromelia virus (ECTV). The number of B820‐27‐specific CD8+ CD44+ T cells in spleen (a) and lung (b) were enumerated on day 6 after infection by dextramer staining. The means of five mice/group ± SEM are shown (**P < 0·005). MHC II −/− immunized as in (a) were infected with 1 × 105 TCID 50 ECTV and monitored twice daily for the appearance of disease symptoms. Symptomatic mice were euthanized. The data are compiled from two independent experiments with n = 4 to n = 8 mice/group. The indicated P‐value was calculated by Mantel–Cox test.